Fig. 4From: Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatmentCells with normal BRCA1/2 or with one normal allele can compensate for double-strand break repair in the presence of PARP inhibitors. On the other hand, using PARP inhibitors in tumor cells with double-negative BRCA1/2 accumulate DSB, which leads to cell deathBack to article page